CN105055555A - Traditional Chinese medicine composition and preparation method, application and preparation thereof - Google Patents
Traditional Chinese medicine composition and preparation method, application and preparation thereof Download PDFInfo
- Publication number
- CN105055555A CN105055555A CN201510529428.XA CN201510529428A CN105055555A CN 105055555 A CN105055555 A CN 105055555A CN 201510529428 A CN201510529428 A CN 201510529428A CN 105055555 A CN105055555 A CN 105055555A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- parts
- preparation
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition and a preparation method, application and preparation thereof. The traditional Chinese medicine composition comprises, by weight, 10-100 parts of common alstonia leaves, 5-50 parts of pseudo-ginseng, 2-15 parts of Yunnan radix aconiti agrestis, 3-30 parts of astragalus membranaceus and 3-30 parts of angelica sinensis. Pharmacological researches show that the traditional Chinese medicine composition can remarkably relieve the pulmonary alveolitis and pulmonary fibrosis by bleomycin in rats and lower pulmonary fibrosis rat pulmonary coefficients and HYP, NO and MDA levels. The raw materials are easy to obtain, the preparation method is scientific, the pharmacologic action and mechanism are clear, the good effect of treating both symptoms and root causes of pulmonary fibrosis is achieved, and the application prospect is wide.
Description
Technical field
The invention belongs to Chinese medicine to learn a skill field, be specifically related to a kind of Chinese medicine composition and preparation method thereof, purposes and preparation.
Background technology
Pulmonary fibrosis (pulmonaryfibrosis, PF) be that to assemble with proliferation of lung fibroblast and ECM be the pathological changes of feature, its early stage pathology is characterized as Diffuse alveolar inflammation and alveolar structure destroys, extracellular matrix over-deposit thereupon, then progress is diffuse interstitial pulmonary fibrosis, finally causes respiratory failure and causes patient death.Many chronic lung diseases, comprise asthma, chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease, pulmonary tuberculosis, pulmonary carcinoma, pneumonia etc., all with pulmonary fibrosis pathological change.Except pulmonary disease, dust, haze, chemicals etc. are also the main inducing of pulmonary fibrosis.In recent years, along with the aggravation of the environmental pollution such as air, water and soil, China's pulmonary fibrosis disease sickness rate increases fast with the speed of more than 20% every year, and patient is only 3-4 the mean survival time.At present, the treatment of pulmonary fibrosis, except lung transplantation, also lacks effective medicine.Though doctor trained in Western medicine adopts the Drug therapys such as glucocorticoid, interferon, pirfenidone clinically, effect is undesirable, and toxic and side effects is large, and the total survival rate of patient is not significantly improved.In the traditional Chinese medical science, pulmonary fibrosis can belong to " consumptive lung disease " category.Compare western medicine and medical practitioners, Chinese medicine has unique advantage to chronic disease and organic degeneration disease, especially the treatment of Chinese medicine to " consumptive lung disease " have accumulated 1,100 enrich clinical data, therefore, the mechanism of further investigation pulmonary fibrosis, before summing up, absorbing human therapy " consumptive lung disease " successful experience basis on, research and development is treated the Traditional chinese medicine medicament of pulmonary fibrosis and is of great practical significance.
Summary of the invention
The first object of the present invention is to provide a kind of Chinese medicine composition; Second object is to provide the preparation method of described Chinese medicine composition; 3rd object is to provide the application of described Chinese medicine composition; 4th object is to provide the clinical preparation of described Chinese medicine composition.
The first object of the present invention is achieved in that and the invention provides a kind of Chinese medicine composition, and it is prepared from by the crude drug of following weight proportion:
Folium Alstoniae Scholaris 10-100 part, Radix Notoginseng 5-50 part, Radix Aconiti Kusnezoffii 2-15 part, Radix Astragali 3-30 part, Radix Angelicae Sinensis 3-30 part.
As preferably, Chinese medicine composition of the present invention is prepared from by the crude drug of following weight proportion:
Folium Alstoniae Scholaris 30 parts, Radix Notoginseng 15 parts, Radix Aconiti Kusnezoffii 5 parts, the Radix Astragali 10 parts, Radix Angelicae Sinensis 10 parts.
The second object of the present invention is achieved in that the preparation method that the invention provides a kind of above-mentioned Chinese medicine composition, it is characterized in that comprising the steps:
A, Folium Alstoniae Scholaris, Radix Aconiti Kusnezoffii pulverized 10 mesh sieves, the mass ratio adding medical material weight 2-3 times amount is the acetic acid-ethanol-water mixed solvent of 0.1 ~ 0.5:15 ~ 20:79.5 ~ 84.9, airtight standing immersion 8 ~ 12 hours, proceed in percolator, with ethanol percolate extraction 32 ~ 36h that the mass concentration of medical material weight 10 ~ 12 times amount is 30 ~ 70%, collect percolate, filter, obtain filtrate A;
B, Radix Notoginseng, the Radix Astragali, Radix Angelicae Sinensis pulverized 50 mesh sieves, divided three reflux, extract, with the ethanol that mass concentration is 60 ~ 90%, and extracting solution filters, and obtains liquor B;
C, merging filtrate A and liquor B, powdered in 40 ~ 60 DEG C of vacuum spray dryings, to obtain final product.
In the step b of above-mentioned preparation method, first time extracts, and solvent load is 8-10 times of medical material weight, and extraction time is 3 hours; Second time is extracted, and solvent load is 5-7 times of medical material weight, 2 hours extraction times; Third time extracts, and solvent load is 2-4 times of medical material weight, and extraction time is 1 hour.
The third object of the present invention is achieved in that the invention provides Chinese medicine composition of the present invention is preparing the application prevented and treated in pulmonary fibrosis medicine.
The fourth object of the present invention realizes like this, the invention provides the clinical preparation of Chinese medicine composition of the present invention, described preparation is by the pharmaceutical formulations adding pharmaceutically acceptable adjuvant or complementary composition in described Chinese medicine composition and be prepared from, and comprises tablet, capsule, granule, pill, powder, oral liquid and unguentum.
In Chinese medicine composition of the present invention, crude drug Folium Alstoniae Scholaris is the dry blade of apocynaceae plant Cornus controversa Alstoniascholaris (L.) R.Bro., for traditional Dai Nationality medicine, Dai Nationality doctor claims " buying load not ", cures mainly " being that many emperors sound of sighing row advanced in years are practised special next " (cough due to lung-heat's abundant expectoration).Modern study shows, Folium Alstoniae Scholaris mainly comprises the chemical compositions such as alkaloids, flavonoid, triterpenes, volatile oil, steroid, there is antitumor, antibacterial, antiinflammatory, eliminate the phlegm, antitussive, the pharmacological action such as to relieving asthma.
In Chinese medicine composition of the present invention, crude drug Radix Notoginseng is the dry root of araliaceae ginseng plant Radix Notoginseng Panaxnotoginseng (Burk) F.H.Chen, has the remarkable efficacy of promoting blood circulation and hemostasis, subduing swelling and relieving pain, is China's tradition rare medicinal herbs.Modern study shows, Radix Notoginseng is mainly containing effective active compositions such as saponin, flavone, volatile oil, aminoacid, polysaccharide and trace element, wherein, Radix Notoginseng total arasaponins (PNS) has the pharmacological actions such as anticoagulant, anticoagulant, antithrombotic, is the main effective site of pseudo-ginseng blood-circulation-invigovating blood stasis dispelling.
In Chinese medicine composition of the present invention, crude drug Radix Aconiti Kusnezoffii is the dried root of cohosh Dendrobium denneanum Kerr. crow AconitumvilmorinianumKomarov or South Yunnan Radix Aconiti Kusnezoffii AconitumaustroyunnanenseW.T.Wang.Excavate when autumn, winter, stem and leaf was withered, remove residual stem, fibrous root, put in boiling water and boil 4-8 hour, scrape off crust, be cut into the thick straight sheet of 2 ~ 5mm or inclined tab, dry and obtain.Modern study shows, the main component of Radix Aconiti Kusnezoffii is aconitine and hypaconitine, has the pharmacological action such as antiinflammatory, analgesia.
In Chinese medicine composition of the present invention, the crude drug Radix Astragali is the dry root of leguminous plant Radix Astagali Astragalusmembranaceus (Fisch.) Bge.var.mongho-licus (Bge.) Hsiao or Radix Astragali Astragalusmembranaceus (Fisch.) Bge..This product nature and flavor are sweet, warm, return lung, spleen channel, have invigorating QI to consolidate the body surface resistance, diuresis poison holding, the effects such as evacuation of pus sore, are usually used in the treatment of the diseases such as the deficiency of vital energy is weak, interior-heat is quenched one's thirst, chronic nephritis, albuminuria and diabetes.Modern study shows, the chemical composition of the Radix Astragali mainly comprises saponin, polysaccharide, flavone, vitamin, fatty acid and trace element etc.
In Chinese medicine composition of the present invention, crude drug is when the dry root being classified as umbelliferae angelica Angelicasinensis (Oliv.) Diels.Autumn end excavates, and removing fibrous root and silt, after moisture slightly evaporates, be bundled into wisp, upper canopy, with pyrotechnics slowly smoke-dried beancurd.This product have enrich blood invigorate blood circulation, effect of menstruction regulating and pain relieving, be usually used in the treatment of the diseases such as blood deficiency, amenorrhea, traumatic injury.
Pulmonary fibrosis can be divided into two classes according to its cause of disease clinically: i.e. idiopathic pulmonary fibrosis and Secondary cases pulmonary fibrosis.This two classes pulmonary fibrosis disease feature is that Diffuse alveolar is scorching and alveolar structure is disorderly and finally causes fibrosis, clinical manifestation is cough, expectoration, there is the symptoms such as the dyspnea that Progressive symmetric erythrokeratodermia increases the weight of in the later stage, and in chronic process, recurrent exerbation, therefore this disease is classified as " consumptive lung disease ", " lung-QI stagnation syndrome " category of the traditional Chinese medical science by most scholar.Theory of Chinese medical science is thought, this sick pathogenesis is that paathogenic factor invades to human body, is detained, causes damage to lungs, and then involve spleen, kidney in lung, causes lung kidney spleen all empty.Their early stage, at gas, then causes QI and blood deficiency and phlegm and blood stasis along with the time increases, the state of an illness belongs to deficiency in origin and excess in superficiality, and Gu Zhiyi astringes the lung benefiting QI and nourishing blood for this, and double invigorating blood circulation to eliminate the phlegm is taken stopgap measures.In Chinese medicine composition of the present invention, Radix Astragali invigorating the lung and benefiting vital QI, Radix Angelicae Sinensis spleen reinforcing benefit blood, pseudo-ginseng blood-circulation-invigovating blood stasis dispelling, Folium Alstoniae Scholaris expectorant cough suppressant and anti-asthmatic, Radix Aconiti Kusnezoffii kidney tonifying is supporing yang, and all medicine conbined usage, work in coordination with each other, pulmonary fibrosis are played to the good result for the treatment of both the principal and secondary aspects of a disease.
The present inventor adopts bleomycin to cause Model of Bleomycin-induced Pulmonary Fibrosis, the pulmonary fibrosis resistant effect of systematic study Chinese medicine composition of the present invention and the mechanism of action thereof.Result shows, and Chinese medicine composition of the present invention significantly can alleviate alveolitis and the pulmonary fibrosis degree of lung fibrosis in rats, reduces paragonimus cyst and HYP, NO and MDA level of lung fibrosis in rats.This shows, Chinese medicine composition of the present invention has significant pulmonary fibrosis resistant effect, may be used for the treatment of pulmonary fibrosis disease.This experimental result is also pointed out, and the anti-fibrosis effect of Chinese medicine composition of the present invention and may suppress collagenation in lung tissue relevant with the antiinflammatory of its increase body, oxidation resistance.
Traditional Chinese medicine composite source of the present invention is easy to get, and preparation method is scientific and reasonable, pharmacological action and clear mechanism, can play the good result for the treatment of both the principal and secondary aspects of a disease, have broad application prospects to pulmonary fibrosis.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is further illustrated, but limited the present invention never in any form, and any conversion done based on training centre of the present invention or replacement, all belong to protection scope of the present invention.
Chinese medicine composition of the present invention, it is prepared from by the crude drug of following weight proportion:
Folium Alstoniae Scholaris 10-100 part, Radix Notoginseng 5-50 part, Radix Aconiti Kusnezoffii 2-15 part, Radix Astragali 3-30 part, Radix Angelicae Sinensis 3-30 part.
As preferably, it is prepared from by the crude drug of following weight proportion:
Folium Alstoniae Scholaris 30 parts, Radix Notoginseng 15 parts, Radix Aconiti Kusnezoffii 5 parts, the Radix Astragali 10 parts, Radix Angelicae Sinensis 10 parts.
The preparation method of Chinese medicine composition of the present invention, comprises the steps:
A, Folium Alstoniae Scholaris, Radix Aconiti Kusnezoffii pulverized 10 mesh sieves, the mass ratio adding medical material weight 2-3 times amount is the acetic acid-ethanol-water mixed solvent of 0.1 ~ 0.5:15 ~ 20:79.5 ~ 84.9, airtight standing immersion 8 ~ 12 hours, proceed in percolator, with ethanol percolate extraction 32 ~ 36h that the mass concentration of medical material weight 10 ~ 12 times amount is 30 ~ 70%, collect percolate, filter, obtain filtrate A;
B, Radix Notoginseng, the Radix Astragali, Radix Angelicae Sinensis pulverized 50 mesh sieves, divided three reflux, extract, with the ethanol that mass concentration is 60 ~ 90%, and extracting solution filters, and obtains liquor B;
C, merging filtrate A and liquor B, powdered in 40 ~ 60 DEG C of vacuum spray dryings, to obtain final product.
In step b, first time extracts, and solvent load is 8-10 times of medical material weight, and extraction time is 3 hours; Second time is extracted, and solvent load is 5 ~ 7 times of medical material weight, 2 hours extraction times; Third time extracts, and solvent load is 2-4 times of medical material weight, and extraction time is 1 hour.
Chinese medicine composition of the present invention is preparing the application prevented and treated in pulmonary fibrosis medicine.
The preparation of Chinese medicine composition of the present invention, is by the pharmaceutical formulations adding pharmaceutically acceptable adjuvant or complementary composition in described Chinese medicine composition and be prepared from, comprises tablet, capsule, granule, pill, powder, oral liquid and unguentum etc.
With specific embodiment, the invention will be further described below:
The preparation of embodiment 1 Chinese medicine composition 1
1. medical material Ji Yuan and the place of production
Folium Alstoniae Scholaris: be the dried leaves of apocynaceae plant Cornus controversa.August 21 in 2010 gathers in Pu'er, Yunnan Province, and former plant is accredited as apocynaceae plant Cornus controversa through Kunming drug research institute of pharmacy group Zhou Rongguang senior engineer.
Radix Notoginseng: be the dry root of araliaceae ginseng plant Radix Notoginseng, the place of production is Yunnan mountain of papers, by Yunnan Province wholeheartedly hall Chinese herbal medicine company limited provide.
Radix Aconiti Kusnezoffii: be the dried root of cohosh South Yunnan Radix Aconiti Kusnezoffii.On November 8th, 2010 gathers in Mengzi, Yunnan Province, and former plant is accredited as cohosh South Yunnan Radix Aconiti Kusnezoffii through Kunming drug research institute of pharmacy group Zhou Rongguang senior engineer.
The Radix Astragali: be the dry root of leguminous plant Radix Astagali.The place of production be Mongolia, by Yunnan Province wholeheartedly hall Chinese herbal medicine company limited provide.
Radix Angelicae Sinensis: be the dry root of umbelliferae angelica, the place of production is Dali, by Yunnan Province wholeheartedly hall Chinese herbal medicine company limited provide.
2. prescription
Folium Alstoniae Scholaris 10 parts, Radix Notoginseng 50 parts, Radix Aconiti Kusnezoffii 2 parts, the Radix Astragali 30 parts, Radix Angelicae Sinensis 3 parts.
3. preparation method:
Step 1): take Folium Alstoniae Scholaris, Radix Aconiti Kusnezoffii by recipe quantity, pulverized 10 mesh sieves, the mass ratio adding medical material weight 3 times amount is the acetic acid-ethanol-water mixed solvent of 0.1:15:84.9, airtight standing immersion 8 hours, proceeding in percolator, is the ethanol percolate extraction 32h of 70% by the mass concentration of medical material weight 10 times amount, collects percolate, filter, obtain filtrate A for subsequent use;
Step 2): take Radix Notoginseng, the Radix Astragali, Radix Angelicae Sinensis by recipe quantity, pulverized 50 mesh sieves, divide three reflux, extract, with the ethanol that mass concentration is 60%.First time extracts, and solvent load is 8 times of medical material weight, and extraction time is 3 hours; Second time is extracted, and solvent load is 5 times of medical material weight, 2 hours extraction times; Extraction solvent consumption is 2 times of medical material weight for the third time, and extraction time is 1 hour.After extraction, extracting solution filters, and obtains liquor B, for subsequent use;
Step 3): merging filtrate A and liquor B, powdered in 40-60 DEG C of vacuum spray drying, to obtain final product.
The preparation of embodiment 2 Chinese medicine composition 2
1, medical material Ji Yuan and the place of production
With embodiment 1.
2. prescription
Folium Alstoniae Scholaris 100 parts, Radix Notoginseng 5 parts, Radix Aconiti Kusnezoffii 15 parts, the Radix Astragali 3 parts, Radix Angelicae Sinensis 30 parts.
3. preparation method:
Step 1): take Folium Alstoniae Scholaris, Radix Aconiti Kusnezoffii by recipe quantity, pulverized 10 mesh sieves, the mass ratio adding medical material weight 2 times amount is the acetic acid-ethanol-water mixed solvent of 0.5:20:79.5, airtight standing immersion 12 hours, loading in percolator, is the ethanol percolate extraction 36h of 30% by the mass concentration of medical material weight 12 times amount, collects percolate, filter, obtain filtrate A for subsequent use;
Step 2): take Radix Notoginseng, the Radix Astragali, Radix Angelicae Sinensis by recipe quantity, pulverized 50 mesh sieves, divide three reflux, extract, with the ethanol that mass concentration is 90%.First time extracts, and solvent load is 10 times of medical material weight, and extraction time is 3 hours; Second time is extracted, and solvent load is 7 times of medical material weight, 2 hours extraction times; Extraction solvent consumption is 4 times of medical material weight for the third time, and extraction time is 1 hour.After extraction, extracting solution filters, and obtains liquor B, for subsequent use;
Step 3): merging filtrate A and liquor B, powdered in 40-60 DEG C of vacuum spray drying, to obtain final product.
The preparation of embodiment 3 Chinese medicine composition 3
1, medical material Ji Yuan and the place of production
With embodiment 1.
2. prescription
Folium Alstoniae Scholaris 30 parts, Radix Notoginseng 15 parts, Radix Aconiti Kusnezoffii 5 parts, the Radix Astragali 10 parts, Radix Angelicae Sinensis 10 parts.
3. preparation method:
Step 1): take Folium Alstoniae Scholaris, Radix Aconiti Kusnezoffii by recipe quantity, pulverized 10 sieve meshes, the mass ratio adding medical material weight 2.5 times amount is the acetic acid-ethanol-water mixed solvent of 0.3:17.7:82.0, airtight standing immersion 10 hours, loading in percolator, is the ethanol percolate extraction 35h of 50% by the mass concentration of medical material weight 11 times amount, collects percolate, filter, obtain filtrate A for subsequent use;
Step 2): take Radix Notoginseng, the Radix Astragali, Radix Angelicae Sinensis by recipe quantity, pulverized 50 mesh sieves, divide three reflux, extract, with the ethanol that mass concentration is 70%.First time extracts, and solvent load is 9 times of medical material weight, and extraction time is 3 hours; Second time is extracted, and solvent load is 6 times of medical material weight, 2 hours extraction times; Extraction solvent consumption is 3 times of medical material weight for the third time, and extraction time is 1 hour.After extraction, extracting solution filters, and obtains liquor B, for subsequent use;
Step 3): merging filtrate A and liquor B, powdered in 40-60 DEG C of vacuum spray drying, to obtain final product.
Embodiment 4 Chinese medicine composition pulmonary fibrosis resistant of the present invention function and mechanism is studied
1. test sample
Chinese medicine composition 1 of the present invention: be called for short " compositions 1 ", prepare by the embodiment of the present invention 1;
Chinese medicine composition 2 of the present invention: be called for short " compositions 2 ", prepare by the embodiment of the present invention 2;
Chinese medicine composition 3 of the present invention: be called for short " compositions 3 ", prepare by the embodiment of the present invention 3;
Control drug prednisolone acetate: Zhejiang Province XianJu Pharmacy stock Co., Ltd provides, code H33020758.
2. experimental apparatus and reagent
CHD type optical microscope (Japanese Olympus company); B204-N type electronic balance (Mettler company of Switzerland).
Bleomycin (BLM), Gao Qi pharmaceutical factory of Japanese Hua Yao Co., Ltd. provides; Hydroxyproline (HYP) test kit, NO test kit, malonaldehyde (MDA) test kit, Nanjing is built up biological company limited and is provided.
3, laboratory animal
SD rat, body weight 180-220g, Kunming Medical University's Experimental Animal Center provides.
4, experimental technique
4.1, modeling and administration
SD rat 60, be divided into 6 groups at random, i.e. Normal group, model group, compositions 1 group (10mg/kg), compositions 2 groups (10mg/kg), compositions 3 groups (10mg/kg) and positive control drug prednisolone acetate group (10mg/kg), often organizes 10.Model group and each treatment group rat adopt BLM to copy animal lung fibrosis model, concrete operation step is as follows: rat with 4.5% chloral hydrate intraperitoneal injection of anesthesia, supine surgical platform, fixing head and extremity, routine disinfection, the descending neck median incision of aseptic condition, blunt separation exposes trachea, in the puncture of trachea ring-type carrtilage space, inject BLM (4.5mg/kg), Normal group injects equal-volume normal saline under the same conditions.Immediately that rat is upright after injection, along long axis of body left rotation and right rotation 5-6min, make medicinal liquid be uniformly distributed in the lung of both sides, then skin suture, sterilization, treat that rat regains consciousness Hou Song cleaning grade observation ward, conventionally to raise.After modeling, each treated animal starts according to corresponding body weight gastric infusion in modeling for second day, and normal group and model group then gavage give normal saline, every day 1 time, successive administration 28 days.
4.2, the mensuration of paragonimus cyst
After rat oral gavage administration 28d, weigh, then, 10% chloral hydrate anesthesia is put to death, and takes out lung tissue and weighs.Calculate paragonimus cyst as follows, heavy (the mg)/body weight (g) of paragonimus cyst=lung.Because Pulmonary Fibrosis in Rats Earlier period of inflammation cell oozes out in a large number, a large amount of hypertrophy of fibroblast in late period, collagen over-deposit all can cause paragonimus cyst to increase, so this index of paragonimus cyst can indirect reaction lung fibrosis in rats inflammation and Fibrotic degree.Paragonimus cyst is higher, shows that pulmonary fibrosis degree is more serious.
4.3, lung tissue disease's Neo-Confucianism is observed
After sacrifice of animal, take out bottom right lung tissue 4% formalin and fix, through dehydration of alcohol step by step, dimethylbenzene is transparent, waxdip, paraffin embedding, conventionally cuts into slices 4 μm, and rear row HE dyes.With reference to the alveolitis of Szapiel method optical microphotograph Microscopic observation determination lung tissue and the degree of pulmonary fibrosis, be divided into level Four: 0 grade, without obviously changing; 1 grade, MC, extent of disease is less than 20% of full lung; 2 grades of moderates change, and extent of disease accounts for the 20%-50% of full lung; 3 grades of severes change, and extent of disease accounts for more than 50% of full lung.
4.4, the detection of lung tissue HYP, NO level
After sacrifice of animal, by lung tissue stripping and slicing, immerse 0.9% normal saline, prepare lung homogenate, adopt hydroxyproline (HYP), NO test kit, according to test kit operating instruction, detect HYP, NO level of lung tissue.
4.5, pulmonary artery MDA content detection
Each group of rat is after perfusion 28d, and 10% chloral hydrate anesthesia (350mg/kg), gets pulmonary artery blood, adopts MDA test kit, measures pulmonary artery contents of mda.
5, experimental result
5.1 Chinese medicine compositions of the present invention are on the impact of lung fibrosis in rats alveolitis and pulmonary fibrosis degree
Experimental rat lung tissue to walk abreast HE dyeing through paraffin section, observed result display under light microscopic: normal group lung tissue structure is clear, and alveolar space is bright, and alveolar wall is complete, and alveolar septum has no and thickens, has no cell infiltration; Model group lung tissue structure is disorderly, and inflammatory cell infiltration is extensive, and alveolar space narrows or disappears, and alveolar septum significantly thickens, a large amount of fibroblast proliferation of interstitial lung and Collagen fiber deposition, and significantly, prompting interstitial pulmonary fibrosis is formed for alveolitis and pulmonary fibrosis degree; Compared with model group, alveolitis and the pulmonary fibrosis course of disease degree of Chinese medicine composition group rat of the present invention obviously alleviate.In table 1.
Table 1 is on the impact of lung fibrosis in rats alveolitis and pulmonary fibrosis degree
From above-mentioned experimental data, Chinese medicine composition of the present invention obviously can alleviate alveolitis and the pulmonary fibrosis degree of lung fibrosis in rats.
5.2 Chinese medicine compositions of the present invention are on the impact of lung fibrosis in rats paragonimus cyst and biochemical indicator
Chinese medicine composition of the present invention on the impact of lung fibrosis in rats paragonimus cyst and biochemical indicator in table 2
Table 2 is on the impact of lung fibrosis in rats paragonimus cyst and biochemical indicator
This index of paragonimus cyst can react lung fibrosis in rats inflammation and Fibrotic degree, and paragonimus cyst is higher, shows that pulmonary fibrosis degree is more serious, otherwise, then represent pulmonary fibrosis degree and reduce.HYP, as body collagen protein main component, accounts for total amino acid content 13%, and the HYP of other elastin laminins also containing different content, so HYP content can be used as the important indicator of collagen tissue metabolism in tissue.Lipid peroxide MDA content can reflect lung inner lipid extent of peroxidation indirectly.
From above-mentioned experimental data, Chinese medicine composition of the present invention significantly can reduce paragonimus cyst and HYP, NO and MDA level of lung fibrosis in rats, this shows that Chinese medicine composition of the present invention has significant therapeutic effect to pulmonary fibrosis, and point out simultaneously, its anti-fibrosis effect may be relevant with suppressing the generation of collagen in lung tissue, and may be realize its treatment to pulmonary fibrosis by antioxidation.
6, conclusion
Chinese medicine composition of the present invention causes Pulmonary Fibrosis in Rats experiment through bleomycin and shows, it significantly can alleviate alveolitis and the pulmonary fibrosis degree of lung fibrosis in rats, reduces paragonimus cyst and HYP, NO and MDA level of lung fibrosis in rats.This absolutely proves, it has significant pulmonary fibrosis resistant effect, may be used for the treatment of pulmonary fibrosis disease.This experimental result is also pointed out, and the anti-fibrosis effect of Chinese medicine composition of the present invention and may suppress collagenation in lung tissue relevant with the antiinflammatory of its increase body, oxidation resistance.
Embodiment 5 tablet
Chinese medicine composition 35% of the present invention
Starch 59%
Microcrystalline Cellulose 6%
By the invention described above Chinese medicine composition, starch, microcrystalline Cellulose mixing after on tablet machine tabletting, to obtain final product.
Embodiment 6 capsule
Chinese medicine composition 30% of the present invention
Starch 70%
After the invention described above Chinese medicine composition is mixed with starch, be packed in hard gelatin capsule, obtain final product.
Embodiment 7 oral liquid
Chinese medicine composition 15% of the present invention
Citric acid 0.5%
Sucrose 6.5%
Distilled water 78%
By the invention described above Chinese medicine composition, citric acid, sucrose and distilled water stirring and evenly mixing, load in oral liquid bottle, to obtain final product.
Claims (6)
1. a Chinese medicine composition, is characterized in that it is prepared from by the crude drug of following weight proportion:
Folium Alstoniae Scholaris 10-100 part, Radix Notoginseng 5-50 part, Radix Aconiti Kusnezoffii 2-15 part, Radix Astragali 3-30 part, Radix Angelicae Sinensis 3-30 part.
2. Chinese medicine composition according to claim 1, is characterized in that it is prepared from by the crude drug of following weight proportion:
Folium Alstoniae Scholaris 30 parts, Radix Notoginseng 15 parts, Radix Aconiti Kusnezoffii 5 parts, the Radix Astragali 10 parts, Radix Angelicae Sinensis 10 parts.
3. a preparation method for Chinese medicine composition described in claim 1 or 2, is characterized in that comprising the steps:
A, Folium Alstoniae Scholaris, Radix Aconiti Kusnezoffii pulverized 10 mesh sieves, the mass ratio adding medical material weight 2-3 times amount is the acetic acid-ethanol-water mixed solvent of 0.1 ~ 0.5:15 ~ 20:79.5 ~ 84.9, airtight standing immersion 8 ~ 12 hours, proceed in percolator, with ethanol percolate extraction 32 ~ 36h that the mass concentration of medical material weight 10 ~ 12 times amount is 30 ~ 70%, collect percolate, filter, obtain filtrate A;
B, Radix Notoginseng, the Radix Astragali, Radix Angelicae Sinensis pulverized 50 mesh sieves, divided three reflux, extract, with the ethanol that mass concentration is 60 ~ 90%, and extracting solution filters, and obtains liquor B;
C, merging filtrate A and liquor B, powdered in 40 ~ 60 DEG C of vacuum spray dryings, to obtain final product.
4. the preparation method of Chinese medicine composition according to claim 3, is characterized in that in step b, and first time extracts, and solvent load is 8-10 times of medical material weight, and extraction time is 3 hours; Second time is extracted, and solvent load is 5 ~ 7 times of medical material weight, 2 hours extraction times; Third time extracts, and solvent load is 2-4 times of medical material weight, and extraction time is 1 hour.
5. the Chinese medicine composition described in a claim 1 or 2 is preparing the application prevented and treated in pulmonary fibrosis medicine.
6. the preparation of Chinese medicine composition described in a claim 1 or 2, it is characterized in that described preparation is by the pharmaceutical formulations adding pharmaceutically acceptable adjuvant or complementary composition in described Chinese medicine composition and be prepared from, comprise tablet, capsule, granule, pill, powder, oral liquid and unguentum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510529428.XA CN105055555B (en) | 2015-08-26 | 2015-08-26 | A kind of Chinese medicine composition and preparation method thereof, purposes and preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510529428.XA CN105055555B (en) | 2015-08-26 | 2015-08-26 | A kind of Chinese medicine composition and preparation method thereof, purposes and preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105055555A true CN105055555A (en) | 2015-11-18 |
| CN105055555B CN105055555B (en) | 2018-03-13 |
Family
ID=54485237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510529428.XA Active CN105055555B (en) | 2015-08-26 | 2015-08-26 | A kind of Chinese medicine composition and preparation method thereof, purposes and preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105055555B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857394A (en) * | 2006-03-22 | 2006-11-08 | 广州中医药大学第二临床医学院 | Medicine composition of effective parts for compound Tongmai Chinese medicine oral liquid and its preparing method |
| CN103845413A (en) * | 2012-12-09 | 2014-06-11 | 焦克军 | Traditional Chinese medicine composition for treating senile vaginal bleeding |
-
2015
- 2015-08-26 CN CN201510529428.XA patent/CN105055555B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857394A (en) * | 2006-03-22 | 2006-11-08 | 广州中医药大学第二临床医学院 | Medicine composition of effective parts for compound Tongmai Chinese medicine oral liquid and its preparing method |
| CN103845413A (en) * | 2012-12-09 | 2014-06-11 | 焦克军 | Traditional Chinese medicine composition for treating senile vaginal bleeding |
Non-Patent Citations (2)
| Title |
|---|
| 李安等: "中国优秀硕士学位论文全文数据库 医药卫生科技辑", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 马君等: "肺痹肺痿文献证治规律研究及对肺纤维化中医辨治的启示", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105055555B (en) | 2018-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101721488B (en) | Pharmaceutical composition for treating liver diseases and prepration method thereof | |
| CN1314432C (en) | Infantile lung invigorating asthma relieving ointment | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN103142842B (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN101053619B (en) | Medicine for treating pulmonary fibrosis | |
| CN104107348A (en) | Chinese herbal medicine for blood sugar reducing, and administration method thereof | |
| CN102100737B (en) | Medicinal composition containing general ginsenoside and total salvianolic acid and preparation method thereof | |
| CN105770078A (en) | Pharmaceutical composition as well as preparation and application thereof | |
| CN103432420B (en) | A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof and detection method | |
| CN1165026A (en) | Chinese drugs for treatment of chronic broncheitis and asthma | |
| CN104771451B (en) | A kind of Chinese medical extract and its application with antidepressant effect | |
| CN104095912B (en) | Treat the preparation method of the Chinese patent drug of rheumatism bone disease | |
| CN104490965B (en) | The application of panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V | |
| CN105055555B (en) | A kind of Chinese medicine composition and preparation method thereof, purposes and preparation | |
| CN103202976B (en) | Traditional Chinese medicine extract for treating myasthenia gravis and preparation method thereof | |
| CN101129604B (en) | Antihypelipidemic traditional Chinese medicine producing method | |
| Chhetree et al. | Studies on the hypoglycaemic activity of Aconitum napellus l. roots | |
| CN105797092B (en) | Yiyuan anti-cold mixture | |
| CN104306743A (en) | Traditional Chinese medicine preparation with capabilities of lowering four high and expelling toxin as well as preparation and taking methods of traditional Chinese medicine preparation | |
| CN106138494B (en) | Kidney nourishing composition and production method thereof | |
| CN101904953B (en) | Medicinal composition for diminishing inflammation and relieving pain and preparation method and use thereof | |
| CN100469375C (en) | Medicine for treating hepatitis and its preparing method | |
| CN103285193A (en) | Lung-tonifying capsule for treating lung-distension caused by qi deficiency of lung and kidney and preparation method thereof | |
| CN114712458B (en) | Pharmaceutical composition for treating vascular aging of hypertension and preparation method and application thereof | |
| CN102302528B (en) | Spraying agent for treating asthma and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |